Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-amino-3-hydroxybutyric acid
- Development stage
- Unknown
- Lead developer
- Haisen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
4-amino-3-hydroxybutyric acid (also known as GABOB) is a small molecule anticonvulsant and a derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Developed and manufactured by Haisen Pharmaceutical, it is approved for the treatment of epilepsy. 4-amino-3-hydroxybutyric acid acts as an agonist at GABA receptors, specifically showing affinity for GABA-B receptors, and may also inhibit 4-aminobutyrate aminotransferase (GABA transaminase), the enzyme responsible for GABA degradation. By enhancing GABAergic tone, it stabilizes neuronal excitability and prevents seizure activity. It is primarily administered orally and has been used clinically for several decades as an antiepileptic agent.
- Brand names
- GamibetalBuxaminBogalGabomade
- Other names
- GABOBgamma-amino-beta-hydroxybutyric acidbeta-hydroxy-GABA4-amino-3-hydroxybutanoic acid
02
Targets
GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on 4-amino-3-hydroxybutyric acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-amino-3-hydroxybutyric acid.